Tags

Type your tag names separated by a space and hit enter

Characterization of primate bronchoalveolar mast cells. II. Inhibition of histamine, LTC4, and PGD2 release from primate bronchoalveolar mast cells and a comparison with rat peritoneal mast cells.
J Immunol. 1986 Dec 15; 137(12):3941-5.JI

Abstract

As described in the preceding companion paper, bronchoalveolar lavage (BAL) of the primate Macaca arctoides infected with the nematode Ascaris suum yields a population of cells containing a high proportion of mast cells (21%). Nedocromil sodium, a new drug undergoing clinical evaluation for the treatment of reversible obstructive airways disease, inhibited the release of histamine, LTC4, and PGD2 from these cells challenged with antigen (with IC30 values of 2.1 X 10(-6) M, 2.3 X 10(-6) M, and 1.9 X 10(-6) M, respectively) and with anti-human IgE (IC30 values of 4.7 X 10(-6) M, 1.3 X 10(-6) M, and 1.3 X 10(-6) M, respectively). Cromolyn sodium was essentially inactive. Histamine release from rat peritoneal mast cells induced by anti-rat IgE was, however, inhibited by both nedocromil sodium and cromolyn sodium with IC30 values of 1.1 X 10(-6) M and 5.5 X 10(-7) M, respectively. Both compounds induce phosphorylation of a 78,000 m.w. protein in the rat peritoneal mast cell in the absence of any stimulus at the same concentrations as those required to inhibit histamine release stimulated by anti-IgE. This event may be part of a feedback mechanism to limit degranulation. Nedocromil sodium and cromolyn sodium were equipotent in their ability to inhibit anti-IgE-induced histamine release from rat peritoneal mast cells, but differed markedly in their ability to inhibit histamine release from macaque BAL cells.

Authors

Wells E
No affiliation info available
Jackson CG
No affiliation info available
Harper ST
No affiliation info available
Mann J
No affiliation info available
Eady RP
No affiliation info available

MeSH

AnimalsAntibodies, Anti-IdiotypicAscariasisBronchiCromolyn SodiumHistamine ReleaseImmunoglobulin EMacacaMast CellsNedocromilPeritoneal CavityProstaglandin D2Prostaglandins DPulmonary AlveoliQuinolinesRatsSRS-A

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

2431049

Citation

Wells, E, et al. "Characterization of Primate Bronchoalveolar Mast Cells. II. Inhibition of Histamine, LTC4, and PGD2 Release From Primate Bronchoalveolar Mast Cells and a Comparison With Rat Peritoneal Mast Cells." Journal of Immunology (Baltimore, Md. : 1950), vol. 137, no. 12, 1986, pp. 3941-5.
Wells E, Jackson CG, Harper ST, et al. Characterization of primate bronchoalveolar mast cells. II. Inhibition of histamine, LTC4, and PGD2 release from primate bronchoalveolar mast cells and a comparison with rat peritoneal mast cells. J Immunol. 1986;137(12):3941-5.
Wells, E., Jackson, C. G., Harper, S. T., Mann, J., & Eady, R. P. (1986). Characterization of primate bronchoalveolar mast cells. II. Inhibition of histamine, LTC4, and PGD2 release from primate bronchoalveolar mast cells and a comparison with rat peritoneal mast cells. Journal of Immunology (Baltimore, Md. : 1950), 137(12), 3941-5.
Wells E, et al. Characterization of Primate Bronchoalveolar Mast Cells. II. Inhibition of Histamine, LTC4, and PGD2 Release From Primate Bronchoalveolar Mast Cells and a Comparison With Rat Peritoneal Mast Cells. J Immunol. 1986 Dec 15;137(12):3941-5. PubMed PMID: 2431049.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Characterization of primate bronchoalveolar mast cells. II. Inhibition of histamine, LTC4, and PGD2 release from primate bronchoalveolar mast cells and a comparison with rat peritoneal mast cells. AU - Wells,E, AU - Jackson,C G, AU - Harper,S T, AU - Mann,J, AU - Eady,R P, PY - 1986/12/15/pubmed PY - 1986/12/15/medline PY - 1986/12/15/entrez SP - 3941 EP - 5 JF - Journal of immunology (Baltimore, Md. : 1950) JO - J Immunol VL - 137 IS - 12 N2 - As described in the preceding companion paper, bronchoalveolar lavage (BAL) of the primate Macaca arctoides infected with the nematode Ascaris suum yields a population of cells containing a high proportion of mast cells (21%). Nedocromil sodium, a new drug undergoing clinical evaluation for the treatment of reversible obstructive airways disease, inhibited the release of histamine, LTC4, and PGD2 from these cells challenged with antigen (with IC30 values of 2.1 X 10(-6) M, 2.3 X 10(-6) M, and 1.9 X 10(-6) M, respectively) and with anti-human IgE (IC30 values of 4.7 X 10(-6) M, 1.3 X 10(-6) M, and 1.3 X 10(-6) M, respectively). Cromolyn sodium was essentially inactive. Histamine release from rat peritoneal mast cells induced by anti-rat IgE was, however, inhibited by both nedocromil sodium and cromolyn sodium with IC30 values of 1.1 X 10(-6) M and 5.5 X 10(-7) M, respectively. Both compounds induce phosphorylation of a 78,000 m.w. protein in the rat peritoneal mast cell in the absence of any stimulus at the same concentrations as those required to inhibit histamine release stimulated by anti-IgE. This event may be part of a feedback mechanism to limit degranulation. Nedocromil sodium and cromolyn sodium were equipotent in their ability to inhibit anti-IgE-induced histamine release from rat peritoneal mast cells, but differed markedly in their ability to inhibit histamine release from macaque BAL cells. SN - 0022-1767 UR - https://www.unboundmedicine.com/medline/citation/2431049/Characterization_of_primate_bronchoalveolar_mast_cells__II__Inhibition_of_histamine_LTC4_and_PGD2_release_from_primate_bronchoalveolar_mast_cells_and_a_comparison_with_rat_peritoneal_mast_cells_ DB - PRIME DP - Unbound Medicine ER -